TY - JOUR
T1 - Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression
AU - Sato, Seiya
AU - Itamochi, Hiroaki
AU - Oumi, Nao
AU - Chiba, Youhei
AU - Oishi, Tetsuro
AU - Shimada, Muneaki
AU - Sato, Shinya
AU - Chikumi, Jun
AU - Nonaka, Michiko
AU - Kudoh, Akiko
AU - Komatsu, Hiroaki
AU - Harada, Tasuku
AU - Sugiyama, Toru
N1 - Publisher Copyright:
© 2016, Japan Human Cell Society and Springer Japan.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - A new cell line of human ovarian clear cell carcinoma (CCC), TU-OC-2, was established and characterized. The cells were polygonal in shape, grew in monolayers without contact inhibition and were arranged in islands like pieces of a jigsaw puzzle. The chromosome numbers ranged from 41 to 96. A low rate of proliferation was observed and the doubling time was 37.5 h. The IC50 values of cisplatin, 7-ethyl-10-hydroxycamptothecin (SN38), which is an active metabolite of camptothecin, and paclitaxel were 7.7 μM, 17.7 nM and 301 nM, respectively. The drug sensitivity assay indicated that TU-OC-2 was sensitive to SN38, but resistant to cisplatin and paclitaxel. Mutational analysis revealed that TU-OC-2 cells have no mutations of PIK3CA in exons 9 and 20 and of TP53 in exons 4–9. We observed the loss of ARID1A protein expression in TU-OC-2 cells by western blot analysis and in the original tumor tissue by immunohistochemistry. This cell line may be useful for studying the chemoresistant mechanisms of CCC and exploring novel therapeutic targets such as the ARID1A-related signaling pathway.
AB - A new cell line of human ovarian clear cell carcinoma (CCC), TU-OC-2, was established and characterized. The cells were polygonal in shape, grew in monolayers without contact inhibition and were arranged in islands like pieces of a jigsaw puzzle. The chromosome numbers ranged from 41 to 96. A low rate of proliferation was observed and the doubling time was 37.5 h. The IC50 values of cisplatin, 7-ethyl-10-hydroxycamptothecin (SN38), which is an active metabolite of camptothecin, and paclitaxel were 7.7 μM, 17.7 nM and 301 nM, respectively. The drug sensitivity assay indicated that TU-OC-2 was sensitive to SN38, but resistant to cisplatin and paclitaxel. Mutational analysis revealed that TU-OC-2 cells have no mutations of PIK3CA in exons 9 and 20 and of TP53 in exons 4–9. We observed the loss of ARID1A protein expression in TU-OC-2 cells by western blot analysis and in the original tumor tissue by immunohistochemistry. This cell line may be useful for studying the chemoresistant mechanisms of CCC and exploring novel therapeutic targets such as the ARID1A-related signaling pathway.
KW - ARID1A
KW - Chemosensitivity
KW - Establishment
KW - Molecular-targeted therapy
KW - Ovarian clear cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84960093526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960093526&partnerID=8YFLogxK
U2 - 10.1007/s13577-016-0138-6
DO - 10.1007/s13577-016-0138-6
M3 - Article
C2 - 26960408
AN - SCOPUS:84960093526
SN - 0914-7470
VL - 29
SP - 181
EP - 187
JO - Human Cell
JF - Human Cell
IS - 4
ER -
